Embecta Corp.
Financials
Valuation Metrics
Embecta Corp.'s Market Cap is $300M. At end of 2025 it was $683M. Ranked #2949 of 3,121 in US market (top 94%), #1331 of 1,463 on NASDAQ (top 91%), #185 of 205 in Health Care Equipment & Services (top 90%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $300M | US#2,949/3,121 Sec#185/205 |
| Revenue | $1.02B | US#1,871/3,121 Sec#115/205 |
| Net Income | $88M | US#1,680/3,121 Sec#85/205 |
| Total Assets | $1.27B | US#2,359/3,121 Sec#121/205 |
| Net Assets | $-613M | US#3,029/3,121 Sec#200/205 |
| Employees | 1,850 | US#1,724/3,121 Sec#117/205 |
| Value | ||
| P/E | 3.43x | US#24/3,121 Sec#1/205 |
| PEG | 0.62x | US#679/3,121 Sec#31/205 |
| P/S | 0.29x | US#144/3,121 Sec#17/205 |
| EV/EBITDA | 5.80x | US#229/3,121 Sec#7/205 |
| FCF Yield | 54.92% | US#25/3,121 Sec#1/205 |
| Profitability | ||
| ROA | 6.92% | US#805/3,121 Sec#51/205 |
| Op. Margin | 24.85% | US#695/3,121 Sec#18/205 |
| Revenue Growth | -7.60% | US#2,562/3,121 Sec#189/205 |
| Earnings Growth | 5.55% | US#1,187/3,121 Sec#66/205 |
| Financial Health | ||
| Total Debt | $1.50B | US#1,331/3,121 Sec#67/205 |
| FCF | $165M | US#1,495/3,121 Sec#85/205 |
| Cash | $215M | US#1,689/3,121 Sec#98/205 |
| Current Ratio | 1.68x | US#1,482/3,121 Sec#130/205 |
| Net Debt/EBITDA | 4.70x | US#1,961/3,121 Sec#126/205 |
| Dividend | ||
| Div. Yield | 9.07% | US#89/3,121 Sec#2/205 |
| Div. Growth | 1.68% | US#1,093/3,121 Sec#38/205 |
| Payout Ratio | 25.42% | US#8/3,121 Sec#2/205 |
| Performance | ||
| 1Y Return | -64.16% | US#3,040/3,121 Sec#199/205 |
| 1M Return | -2.40% | US#749/3,121 Sec#81/205 |
| From 52W High | -65.04% | US#2,977/3,121 Sec#196/205 |
| 1Y MDD | -80.53% | US#3,069/3,121 Sec#199/205 |
| Trading | ||
| Volume | 2,257,120 shares | US#1,902/3,121 Sec#129/205 |
| Trading Value | $12M | US#2,818/3,121 Sec#176/205 |
| Per Share | ||
| EPS | $1.54 | US#1,496/3,121 Sec#76/205 |
| BPS | $-10.81 | US—/3,121 Sec—/205 |
Company Info
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.